Although the use of bevacizumab showed a good efficacy for CRC treatment, several studies reported various side effects of this anti-angiogenic molecule, the most frequent being hypertension—due to the blockade of VEGF-induced nitric oxide production in normal vessels—and proteinuria—likely due to inhibition of podocyte-derived VEGF [64]. The gene discussed is VEGFA; the disease is colorectal carcinoma.